Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Tesaro Inc (TSRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 6,449,588
  • Shares Outstanding, K 54,180
  • Annual Sales, $ 44,820 K
  • Annual Income, $ -387,470 K
  • 36-Month Beta 1.63
  • Price/Sales 143.45
  • Price/Cash Flow 0.00
  • Price/Book 15.98

Price Performance

See More
Period Period Low Period High Performance
1-Month
114.25 +4.19%
on 09/12/17
136.45 -12.76%
on 09/06/17
-1.58 (-1.31%)
since 08/22/17
3-Month
106.64 +11.63%
on 08/17/17
153.25 -22.32%
on 06/23/17
-30.73 (-20.52%)
since 06/22/17
52-Week
96.52 +23.33%
on 10/07/16
192.94 -38.30%
on 02/21/17
+10.61 (+9.79%)
since 09/22/16

Most Recent Stories

More News
Cancer Space Update: Mixed Week for Pfizer, Roche Falters

Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.

MRK : 65.13 (-0.72%)
KPTI : 10.63 (+1.43%)
TSRO : 119.04 (+0.31%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook

Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.

VRTX : 151.26 (-0.53%)
BMRN : 94.95 (+1.64%)
ABBV : 87.48 (+0.08%)
TSRO : 119.04 (+0.31%)
NBRV : 8.47 (+1.44%)
AMGN : 185.76 (-0.47%)
HALO : 16.78 (+1.08%)
TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion

TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.

HSKA : 89.36 (-0.13%)
AZN : 33.95 (+3.47%)
CLVS : 78.56 (+2.09%)
TSRO : 119.04 (+0.31%)
Corporate News Blog - EMA Grants Positive CHMP Opinion to Tesaro's Ovarian Cancer Drug

Research Desk Line-up: Advaxis Post Earnings Coverage

ADXS : 4.57 (-3.38%)
TSRO : 119.04 (+0.31%)
TESARO Receives Positive CHMP Opinion for ZEJULA(R)

ZUG, Switzerland, Sept. 15, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for...

TSRO : 119.04 (+0.31%)
TESARO Receives Positive CHMP Opinion for ZEJULA(R)

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a...

TSRO : 119.04 (+0.31%)
Veeva R&D Summit to Highlight Life Sciences Shift to Unify Processes in Clinical, Regulatory, and Quality

Veeva Systems today announced details for the 2017 Veeva R&D Summit. The fourth annual event will be held from October 2-4, 2017 in Philadelphia and feature six of the top 25 largest ...

VEEV : 55.68 (-0.82%)
RGNX : 28.25 (-3.91%)
TSRO : 119.04 (+0.31%)
INSM : 28.50 (-1.18%)
BMY : 63.36 (+0.05%)
TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting

MADRID, Spain, Sept. 11, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today provided a summary of ZEJULA and TSR-042, an anti-PD-1 antibody, data...

TSRO : 119.04 (+0.31%)
TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today provided a summary of ZEJULA and TSR-042, an anti-PD-1 antibody, data presented at the 2017 European Society of Medical...

TSRO : 119.04 (+0.31%)
Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal

Gilead's (GILD) $11.8 billion deal to buy Kite Pharma KITE) has made two other leading independent CAR-T developers, Juno and Bluebird Bio hot takeover targets.

CELG : 143.89 (+0.08%)
BLUE : 128.75 (+0.70%)
PBYI : 104.50 (-0.29%)
CLVS : 78.56 (+2.09%)
GILD : 83.27 (+0.79%)
TSRO : 119.04 (+0.31%)
KITE : 179.30 (-0.04%)
JUNO : 45.14 (+8.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor...

See More

Support & Resistance

2nd Resistance Point 121.41
1st Resistance Point 120.22
Last Price 119.04
1st Support Level 117.23
2nd Support Level 115.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.